GSK joins US investment spree with $30B planned for manufacturing, R&D

URLhttps://www.fiercepharma.com/manufacturing/gsk-joi
SourceFierce Pharma
Date Published09/16/2025
Author Name Darren Incorvaia

Additional Reshoring Information:

Company/Division name GSK
Parent companyGSK
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2025
Domestically, the work will be done:In-house
Country(ies) from which reshored:United Kingdom
City reshored to:Upper Merion
State(s) reshored to:PA
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredbiopharmaceuticals
What non-domestic negative factors made offshoring less attractive?Tariffs
What domestic positive factors made reshoring more attractive?Manufacturing/engineering joint innovation (R&D)
Find Reshoring Articles